Nasdaq

Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris

WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
NBC News

How to treat cystic acne, according to dermatologists

Millions of people deal with acne, but those who suffer from cystic acne know how difficult it is to treat compared to ordinary pimples. Cystic acne is a severe form of acne that results in large, pus ...
Medscape

Acne Vulgaris

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity (mild, moderate, severe) and the type(s) of lesion(s) present (noninflammatory, inflammatory, mixed). In general, the ...
Healthline

Understanding the Difference Between Acne Inversa and Acne Vulgaris

Acne vulgaris typically involves outer skin blemishes like pimples, while acne inversa affects deeper layers of the skin, leading to painful nodules. Acne is a skin condition that can cause pimples, ...
Nasdaq

Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical ...

WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received ...